DrugPatentWatch Database Preview
Adapt Company Profile
Email this page to a colleague
» See Plans and PricingWhat is the competitive landscape for ADAPT, and what generic alternatives to ADAPT drugs are available?
ADAPT has two approved drugs.
There are eight US patents protecting ADAPT drugs.
There are twenty-three patent family members on ADAPT drugs in fourteen countries and one supplementary protection certificate in one country.
Summary for Adapt
| International Patents: | 23 |
| US Patents: | 8 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 2 |
| Patent Litigation for Adapt: | See patent lawsuits for Adapt |
Drugs and US Patents for Adapt
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adapt | NARCAN | naloxone hydrochloride | SPRAY, METERED;NASAL | 208411-001 | Nov 18, 2015 | RX | Yes | Yes | 9,211,253 | Start Trial | Y | Start Trial | |||
| Adapt | NARCAN | naloxone hydrochloride | SPRAY, METERED;NASAL | 208411-002 | Jan 24, 2017 | DISCN | Yes | No | 9,480,644 | Start Trial | Y | Start Trial | |||
| Adapt | NARCAN | naloxone hydrochloride | SPRAY, METERED;NASAL | 208411-001 | Nov 18, 2015 | RX | Yes | Yes | 9,775,838 | Start Trial | Start Trial | ||||
| Adapt | NARCAN | naloxone hydrochloride | SPRAY, METERED;NASAL | 208411-001 | Nov 18, 2015 | RX | Yes | Yes | 10,085,937 | Start Trial | Start Trial | ||||
| Adapt | NARCAN | naloxone hydrochloride | INJECTABLE;INJECTION | 016636-002 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | Start Trial | Start Trial | |||||
| Adapt | NARCAN | naloxone hydrochloride | SPRAY, METERED;NASAL | 208411-001 | Nov 18, 2015 | RX | Yes | Yes | 9,629,965 | Start Trial | Y | Start Trial | |||
| Adapt | NARCAN | naloxone hydrochloride | SPRAY, METERED;NASAL | 208411-001 | Nov 18, 2015 | RX | Yes | Yes | 9,561,177 | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for ADAPT drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Nasal Spray | 4 mg/spray | ➤ Subscribe | 2016-07-15 |
International Patents for Adapt Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Spain | 2631504 | Start Trial |
| Japan | 2017508800 | Start Trial |
| Hong Kong | 1231370 | Start Trial |
| Canada | 2950687 | Start Trial |
| Israel | 272294 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2015136373 | Start Trial |
| Mexico | 2016011902 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Adapt Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1685839 | 92292 | Luxembourg | Start Trial | PRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
